Figure 1: ST2 expression in human CRC samples. | Nature Communications

Figure 1: ST2 expression in human CRC samples.

From: Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment

Figure 1

(a) IHC analysis of ST2 expression using human primary CRC tissue arrays. The IHC score was expressed based on the percentage of ST2-positive cells within the total cancerous cells as follows: IHC score 1, 0% positive; IHC score 2, 1–10% positive; IHC score 3, 11–50% positive; IHC score, >50% positive. Scale bars: 100 μm. (b) Correlation between CRC stages and ST2 IHC scores. (c) IHC analysis of ST2 and CD31 expression in consecutive tissue cores. Scale bars: 100 μm. (d) Correlation between CRC stages and the number of tumour microvessels. (e) IHC analysis of ST2 expression in matched primary tumour and liver metastatic lesion samples from CRC patients. Scale bars: 100 and 20 μm for the upper and lower panels, respectively. Note that the ST2 immunostaining was localized in the cytoplasm but not on the cell membranes of the cancerous cells from patients #1 and #2. (f) Serum sST2 levels of patients with various stages of CRC. Left: sST2 level in the sera from patients with various stages of CRC. Right: Maximum tumour diameter of CRC in patients in various CRC stages. The data are shown as the mean±s.d. n.s. not significant, *P<0.05, **P<0.02, ***P<0.001, ****P<0.0001 by Student’s t-test.

Back to article page